337 related articles for article (PubMed ID: 25988772)
1. Pharmacokinetic and pharmacodynamic evaluation of aflibercept for the treatment of colorectal cancer.
Sanz-Garcia E; Saurí T; Tabernero J; Macarulla T
Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):995-1004. PubMed ID: 25988772
[TBL] [Abstract][Full Text] [Related]
2. Ziv-aflibercept: a novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer.
Chung C; Pherwani N
Am J Health Syst Pharm; 2013 Nov; 70(21):1887-96. PubMed ID: 24128964
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapy for metastatic colorectal cancer: role of aflibercept.
Mitchell EP
Clin Colorectal Cancer; 2013 Jun; 12(2):73-85. PubMed ID: 23102896
[TBL] [Abstract][Full Text] [Related]
4. Aflibercept: A Review in Metastatic Colorectal Cancer.
Syed YY; McKeage K
Drugs; 2015 Aug; 75(12):1435-45. PubMed ID: 26220913
[TBL] [Abstract][Full Text] [Related]
5. [Aflibercept (Zaltrap(®)) approved in metastatic colorectal cancer].
André T; Chibaudel B
Bull Cancer; 2013 Oct; 100(10):1023-5. PubMed ID: 24047539
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of aflibercept in the treatment of metastatic colorectal cancer.
Macarulla T; Sauri T; Tabernero J
Expert Opin Biol Ther; 2014 Oct; 14(10):1493-505. PubMed ID: 25152076
[TBL] [Abstract][Full Text] [Related]
7. Emerging VEGF-receptor inhibitors for colorectal cancer.
Martinelli E; Troiani T; Morgillo F; Orditura M; De Vita F; Belli G; Ciardiello F
Expert Opin Emerg Drugs; 2013 Mar; 18(1):25-37. PubMed ID: 23216053
[TBL] [Abstract][Full Text] [Related]
8. Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy.
Ruff P; Ferry DR; Lakomỳ R; Prausová J; Van Hazel GA; Hoff PM; Cunningham D; Arnold D; Schmoll HJ; Moiseyenko VM; McKendrick JJ; Ten Tije AJ; Vishwanath RL; Bhargava P; Chevalier S; Macarulla T; Van Cutsem E
Eur J Cancer; 2015 Jan; 51(1):18-26. PubMed ID: 25466509
[TBL] [Abstract][Full Text] [Related]
9. A preclinical and clinical review of aflibercept for the management of cancer.
Gaya A; Tse V
Cancer Treat Rev; 2012 Aug; 38(5):484-93. PubMed ID: 22264850
[TBL] [Abstract][Full Text] [Related]
10. Adverse events associated with antiangiogenic agents in combination with cytotoxic chemotherapy in metastatic colorectal cancer and their management.
Cartwright TH
Clin Colorectal Cancer; 2013 Jun; 12(2):86-94. PubMed ID: 23562587
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetic analysis of free and bound aflibercept in patients with advanced solid tumors.
Thai HT; Veyrat-Follet C; Mentré F; Comets E
Cancer Chemother Pharmacol; 2013 Jul; 72(1):167-80. PubMed ID: 23673444
[TBL] [Abstract][Full Text] [Related]
12. Ziv-aflibercept (Zaltrap) for the treatment of metastatic colorectal cancer.
Perkins SL; Cole SW
Ann Pharmacother; 2014 Jan; 48(1):93-8. PubMed ID: 24259608
[TBL] [Abstract][Full Text] [Related]
13. Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer.
Tang PA; Cohen SJ; Kollmannsberger C; Bjarnason G; Virik K; MacKenzie MJ; Lourenco L; Wang L; Chen A; Moore MJ
Clin Cancer Res; 2012 Nov; 18(21):6023-31. PubMed ID: 22977191
[TBL] [Abstract][Full Text] [Related]
14. Aflibercept: a novel VEGF targeted agent to explore the future perspectives of anti-angiogenic therapy for the treatment of multiple tumors.
Sharma T; Dhingra R; Singh S; Sharma S; Tomar P; Malhotra M; Bhardwaj TR
Mini Rev Med Chem; 2013 Apr; 13(4):530-40. PubMed ID: 23317499
[TBL] [Abstract][Full Text] [Related]
15. Aflibercept, a New Way to Target Angiogenesis in the Second Line Treatment of Metastatic Colorectal Cancer (mCRC).
Scartozzi M; Vincent L; Chiron M; Cascinu S
Target Oncol; 2016 Aug; 11(4):489-500. PubMed ID: 27412031
[TBL] [Abstract][Full Text] [Related]
16. Targeting Angiogenic Pathways in Colorectal Cancer: Complexities, Challenges and Future Directions.
Khan K; Cunningham D; Chau I
Curr Drug Targets; 2017; 18(1):56-71. PubMed ID: 25808652
[TBL] [Abstract][Full Text] [Related]
17. Is there a benefit from addiction to anti-VEGF therapy in patients with colorectal cancer?
Saif MW
Anticancer Res; 2013 Jun; 33(6):2377-80. PubMed ID: 23749885
[TBL] [Abstract][Full Text] [Related]
18. [New molecular targeting drugs for metastatic colorectal cancer].
Komatsu Y; Harada K; Fukushima H; Yuki S
Nihon Rinsho; 2014 Jan; 72(1):120-6. PubMed ID: 24597359
[TBL] [Abstract][Full Text] [Related]
19. [Cost-effectiveness analysis of aflibercept in combination with FOLFIRI in the treatment of patients with metastatic colorectal cancer].
Pericay C; Frías C; Abad A; Lamas MJ; Echave M; Oyagüez I; Rubio M; Giménez E; Naoshy S; Joulain F
Farm Hosp; 2014 Jul; 38(4):317-27. PubMed ID: 25137165
[TBL] [Abstract][Full Text] [Related]
20. Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept.
González Astorga B; Salvà Ballabrera F; Aranda Aguilar E; Élez Fernández E; García-Alfonso P; González Flores E; Vera García R; Fernández Montes A; López Muñoz AM; Salud Salvia A
Clin Transl Oncol; 2021 Aug; 23(8):1520-1528. PubMed ID: 33630242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
